MYRON MAX LEVINE
Pilots at Windmill Ln, Columbia, MD

5189151, Feb 23, 1993

May 16, 1990

7/524100

Bernadette Baudry - Silver Spring MD
Myron M. Levine - Columbia MD

C07H 2104

536 2432

An oligonucleotide comprises a DNA segment capable of hybridizing to DNA from enteroaggregative E. coli bacteria with high sensitivity and specificity. A recombinant vector comprises a vector carrying the oligonucleotide of the invention, the vector being capable of replication in a host. A host is transformed with the recombinant vector of the invention. A method of detecting the presence of enteroaggregative E. coli DNA in a biological sample with high sensitivity and specificity comprises adding to the sample the labeled oligonucleotide of the invention under conditions effective to promote hybridization thereof to the sample's DNA, and detecting the presence of hybridized labeled DNA. A method of detecting the presence of enteroaggregative E. coli RNA in a sample with high sensitivity and specificity comprises adding to the sample the oligonucleotide of the invention under conditions effective to promote hybridization thereof to the sample's RNA and detecting the presence of hybridized labeled RNA-DNA.

5882653, Mar 16, 1999

Jul 29, 1996

8/624601

James B. Kaper - Columbia MD
Myron M. Levine - Columbia MD

The University of Maryland System - Baltimore MD

A61K 39106, C12N 120

4242611

Avirulent Vibrio cholerae strains of O1 (CVD111) and non-O1 (CVD112 and CVD112RM) serogroups having the DNA of the cholera toxin core and the RS1 sequences of the cholera toxin locus deleted, and further having a DNA encoding a resistance to mercury, and a DNA encoding the cholera toxin B subunit, or a part thereof sufficient to confer immunogenicity, re-inserted in the chromosome. Methods of making the avirulent V. cholerae O1 and non-O1 strains of the invention, and cholera vaccines using these strains.

5628994, May 13, 1997

Dec 1, 1994

8/352773

James B. Kaper - Columbia MD
Myron M. Levine - Columbia MD

The University of Maryland - Baltimore MD

A61K 3566, A61K 3574, C12N 1500

424 932

Method of isolating deletion mutants of Vibrio cholerae, wherein the deletion is predetermined by digestion with restriction endonucleases of known specificity. The deletions are inserted into the Vibrio cholerae chromosome by in vivo recombination between a plasmid carrying the desired deletion, with adjacent flanking sequences, and the Vibrio cholerae chromosome. The invention includes the isolation and characterization of a new Vibrio cholerae strain, CVD103Hg (ATTC No. 55,456), having a deletion in the tox gene, as defined by Acc I, Xba I, Cla I and/or restriction endonuclease sites, and carrying a mercury resistance gene. The invention also includes vaccines for protecting against the symptoms of cholera as well as methods for achieving this protection.

5468639, Nov 21, 1995

Dec 2, 1993

8/160317

Alessio Fasano - Ellicott City MD
Myron M. Levine - Columbia MD
James P. Nataro - Catonsville MD
Fernando Noriega - Columbia MD

University of Maryland at Baltimore - Baltimore MD

C12N 1500, C07H 1900, C07H 2100, C12P 2104

4353201

Substantially pure enterotoxins of Shigella flexneri 2a are described, along with a method for obtaining the same, antibodies having binding specificity to the enterotoxins and a method for use of the enterotoxins to develop a non-reactogenic Shigella flexneri 2a vaccine candidate.

5686580, Nov 11, 1997

Jun 6, 1995

8/471154

Alessio Fasano - Ellicott City MD
Myron M. Levine - Columbia MD
James P. Nataro - Catonsville MD
Fernando Noriega - Columbia MD

University of Maryland at Baltimore - Baltimore MD

C07K 1600, C12P 2108

5303895

Substantially pure enterotoxins of Shigella flexneri 2a are described, along with a method for obtaining the same, antibodies having binding specificity to the enterotoxins and a method for use of the enterotoxins to develop a non-reactogenic Shigella flexneri 2a vaccine candidate.

5589380, Dec 31, 1996

Nov 30, 1994

8/351147

Alessio Fasano - Ellicott City MD
Myron M. Levine - Columbia MD
James P. Nataro - Catonsville MD
Fernando Noriega - Columbia MD

University of Maryland at Baltimore - Baltimore MD

C12N 120, C12P 2104, C07K 100, C07H 1900

4352523

Substantially pure enterotoxins of Shigella flexneri 2a are described, along with a method for obtaining the same, antibodies having binding specificity to the enterotoxins and a method for use of the enterotoxins to develop a non-reactogenic Shigella flexneri 2a vaccine candidate.

6902736, Jun 7, 2005

Apr 20, 2001

09/839894

Zeev Altboum - Ramat Aviv, IL
Myron M. Levine - Columbia MD, US
Eileen M. Barry - Elkridge MD, US

University of Maryland, Baltimore - Baltimore MD

A61K039/108, A61K039/02, A61K039/00

4242421, 4241841, 4241851, 4241901, 4242341, 4242571, 530350

Compositions comprising products of the csa operon, an isolated nucleic acid encoding the csa operon or functional fragments thereof, purified polypeptide products of the csa operon or functional fragments thereof, methods of eliciting an immune response to these products, and methods of producing products of the csa operon are disclosed herein.

7399474, Jul 15, 2008

Feb 10, 2005

11/053876

Zeev Altboum - Ramat Aviv, IL
Myron M. Levine - Columbia MD, US
Eileen M. Barry - Elkridge MD, US

University of Maryland, Baltimore - Baltimore MD

A61K 39/108

4241901, 4242571

Compositions comprising products of the csa operon, an isolated nucleic acid encoding the csa operon or functional fragments thereof, purified polypeptide products of the csa operon or functional fragments thereof, methods of eliciting an immune response to these products, and methods of producing products of the csa operon are disclosed herein.

4935364, Jun 19, 1990

Jun 5, 1989

7/363383

James B. Kaper - Columbia MD
Myron M. Levine - Columbia MD

Swiss Serum and Vaccine Institute Berne - Berne

C12N 1500, C12N 120, C12R 163

4351723

This invention relates to a method of isolating deletion mutants of Vibrio cholerae, wherein the deletion is predetermined by digestion with restriction endonucleases of known specificity. The deletions are inserted into the Vibrio cholerae chromosome by in vivo recombination betweem a plasmid carrying the desired deletion, with adjacent flanking sequences, and the Vibrio cholerae chromosome. The invention includes the isolation and characterization of a new Vibrio cholerae strain having a deletion in the tox gene, as defined by Acc I restriction endonuclease sites.

8137930, Mar 20, 2012

Mar 6, 2009

12/399091

Christofer Vindurampulle - Thornbury, AU
Eileen M. Barry - Ellicott City MD, US
Myron M. Levine - Columbia MD, US
James Galen - Sykesville MD, US

University of Maryland, Baltimore - Baltimore MD

C12P 21/00, C12P 19/04

435 691, 435 712

The present invention is drawn to a live, attenuated A strain, a live, attenuated A strain comprising a stabilized plasmid expression system, an conjugate vaccine, and methods of using these strains and conjugate vaccine.